Abstract The Food and Drug Administration approval of ruxolitinib for treatment of
myelofibrosis and polycythemia vera has changed the management of patients with
myeloproliferative neoplasms. Yet the impact of this therapy on risk of thrombosis, a major
cause of morbidity and mortality among these patients, remains unknown. The aim of this
study was to evaluate the impact of ruxolitinib on the risk of thrombosis among patients with
polycythemia vera or myelofibrosis. Following identification of randomized controlled trials …